Click here to view TB Alliance financial information for the year ending December 31, 2008

Such financial statements are presented for convenience and information purposes only, and while reasonable efforts have been made to ensure the integrity of such information, they should not be relied on.  A copy of the printed financial statements will be provided on request

Based on an analysis of interviews with 211 key stakeholders in Brazil, China, India, Kenya and South Africa - five countries with high TB burdens - and with 11 global stakeholders, this report explores, for the first time, how decision makers prioritize various attributes when considering adoption of new TB regimens.

This document outlines the policy of the Global Alliance for TB Drug Development (TB Alliance) on the compassionate or emergency use outside the scope of clinical trials, of experimental products in its development portfolio that are not yet approved by regulatory authorities